Clinical Trials

644 enrolled 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03517449 2026-03-19

MK-3475-775

827 enrolled 34 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled 1 FDA

Breast Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 1 FDA

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT04472429 2025-11-03

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

308 enrolled 17 charts 1 FDA

Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03036488 2025-10-29

MK-3475-522

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03981796 2025-09-03

RUBY

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT04209855 2025-08-27

MIRASOL

453 enrolled 18 charts 1 FDA

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03800134 2025-06-11

AEGEAN

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

559 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 1 FDA

Breast Neoplasms

NCT02220894 2023-10-10

Keynote 042

1,274 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02564263 2023-03-13

KEYNOTE-181

628 enrolled 27 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

419 enrolled 20 charts 1 FDA

Gastrointestinal

Esophageal Neoplasms

NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,873 enrolled 17 charts 1 FDA